The Semaglutide market is projected to expand from US$ 27.15 billion in 2024 to US$ 61.7 billion by 2033, with a CAGR of 9.55% from 2025. Driven by r ...

In its order, CJ Upadhyaya-led bench directed PIL litigant to submit to CDSCO the scientific studies and data relied upon in ...

Two of the distinguished in the latest edition of the Fronteras del Conocimiento FBBVA, endocrinologist Daniel J. Drucker and ...

While real-time data on how Indians are responding to these drugs is still emerging, experts say that sustained weight loss ...

Ypsomed announced today that Chinese regulatory authorities approved the a dual GCP/GLP-1 drug delivered using its ...

HOUSTON, TEXAS / ACCESS Newswire / July 1, 2025 / EON Resources Inc. (NYSE American:EONR) (“EON” or the “Company”) is an ...

The annual meeting of the American Diabetes Association was held this year from June 20 to 23 in Chicago, drawing more than ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

GLP-1RA use initially lowered delirium risk but eventually heightened delirium risk after 5 years among patients with type 2 diabetes.

Glucagon-like peptide-1 (GLP-1) injections such as Wegovy (semaglutide) and Zepbound (tirzepatide) are the most effective weight-loss medications available today. Oral GLP-1 pills, such as ...

MET-097 is a glucagon-like peptide 1 receptor (GLP-1R) agonist developed at Metsera for treating overweight and obesity and is currently in phase II clinical trials.